Traders News Source, a major independent equity research & corporate access entity focused on small and mid-cap public entities is issuing a report with no onus on Novavax, Inc. (NASDAQ:NVAX), a clinical-phase vaccine firm concentrated on the discovery, commercialization and advancement of recombinant nanoparticle inoculations and adjuvants.
The firm works through the recombinant vaccines division. Using its recombinant nanoparticle vaccine know-how, the company develops vaccine candidates to respond to known and new diseases.
On September 15, 2016, Novavax posted negative data of its respiratory syncytial virus, vaccine study for older adults. The firm’s stock dropped to $1.29/share from $7.79/share on the update and has yet to recover. RSV is a usual source of harmful infections in infants and the elders, leading to a projected 16,000 deaths and sickening 900,000 older adults.
The firm continues to see future in RSV vaccines, now shifting its focus on its RSV vaccine product candidate for infants through maternal immunization. Novavax continues to consider there is a lucrative market prospect for the RSV-F franchise, and expects bringing the preliminary RSV vaccine to market.
The firm recently reported financial report and business progress for Q1 2017. Novavax recorded a net loss of $43.9 million against a net loss of $77.3 million, for Q1 2016. Revenue jumped 35% to $5.7 million, against $4.2 million for the equivalent period in 2016, mainly due to higher revenue seen under the BMGF grant pertaining to underway Prepare clinical trial. Equities experts predict that company will record ($0.62) in earnings per share for 2017.
As per management, the firm continues to make considerable progress in the implementation of its two major clinical studies of RSV F vaccine for infant through maternal immunization and also in older adults.
In the last trading session, the stock price of Novavax declined more than 3% to close the day at $0.960.